Mandibular advancement devices (MADs) have emerged as an effective alternative treatment for obstructive sleep apnea (OSA), particularly in patients with mild to moderate disease or intolerance to continuous positive airway pressure (CPAP). The authors designed a new MAD and presented results of our 6 adult patients, accompanied by current evidence on the efficacy, mechanisms, clinical outcomes, and limitations of MAD therapy. MAD therapy significantly reduces apnea-hypopnea index (AHI), improves oxygen saturation, and enhances subjective sleep quality. Although CPAP achieves greater AHI reduction, MADs demonstrate comparable improvements in daytime sleepiness and quality of life, with higher patient adherence. Also, our patients’ apneas, snoring, and daytime sleepiness decreased while sleep quality and quality of life increased. Adverse effects are generally mild and include temporomandibular discomfort and long-term dental changes. Only one of our patients had a toothache, and it resolved soon. MADs represent a validated and patient-friendly treatment option for selected OSA patients. Advances in device design and individualized titration protocols may further enhance efficacy and reduce adverse effects.
Sidika Deniz Yalim (Thu,) studied this question.